xAnts

Tecentriq Breakthrough: Roche's Immunotherapy Significantly Improves Outcomes for High-Risk Colon Cancer Patients

Reuters

Roche's Tecentriq Shows Promise in Reducing Recurrence and Mortality in Colon Cancer In a significant advancement for colon cancer treatment, Roche's immunotherapy drug, Tecentriq (atezolizumab), has demonstrated remarkable results in a recent clini ...Read more